Loading...
XSHE
300725
Market cap1.08bUSD
Jul 09, Last price  
36.30CNY
1D
1.94%
1Q
-4.45%
IPO
366.58%
Name

PharmaBlock Sciences Nanjing Inc

Chart & Performance

D1W1MN
XSHE:300725 chart
P/E
39.77
P/S
3.70
EPS
0.91
Div Yield, %
0.77%
Shrs. gr., 5y
0.92%
Rev. gr., 5y
10.44%
Revenues
1.97b
+16.93%
58,547,36276,639,124136,130,804188,377,857273,250,557478,254,313662,230,9321,022,229,2151,201,629,0701,594,699,9781,594,699,9771,725,203,9851,688,619,6461,974,477,816
Net income
184m
-16.31%
18,247,14522,471,46419,934,49036,115,20767,179,208133,363,382152,068,788184,207,685486,559,408314,223,824314,223,827197,360,949219,539,838183,735,514
CFO
667m
+120.38%
18,316,10011,909,55427,524,48422,757,68854,639,657160,161,084127,044,730271,505,518238,029,950246,608,762246,839,976302,823,004667,360,829
Dividend
May 30, 20250.28 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PharmaBlock Sciences (Nanjing), Inc. delivers a comprehensive suite of chemical products and specialized services, supporting the pharmaceutical industry across the full spectrum of its operations – from initial research and development phases to large-scale commercial production. The company's primary offerings encompass: A vast inventory of chemical building blocks, available for supply at every stage of drug creation, from early discovery through to advanced development and commercial manufacturing. The creation of diverse chemical libraries, derived from their building blocks, specifically designed to accelerate drug discovery processes. Contract development and manufacturing (CDMO) services for essential pharmaceutical components, including raw starting materials (RSMs), chemical intermediates, active pharmaceutical ingredients (APIs), and finished drug products, catering to both clinical development programs and market demands. Established in 2006, PharmaBlock Sciences maintains its corporate headquarters in Nanjing, People's Republic of China.
IPO date
Nov 10, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT